Detection of primary and metastatic lesions by [18F]fluoro-2- deoxy-D-glucose PET in a patient with thymic carcinoid

Respirology

Volumn 12, Issue 6, 2007, Pages 928-930

  Fujishita, Takashi ^a   Kishida, Mika ^a   Taki, Hirofumi ^a   Shinoda, Chie ^a   Miyabayashi, Koutarou ^a   Fujishita, Masayo ^a   Maruyama, Muneharu ^a   Mizushima, Yutaka ^b   Kobayashi, Masashi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

123I MIBG; 99mTc MDP bone scintigraphy; FDG PET; Thymic carcinoid

Indexed keywords

CARBOPLATIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M; METAIODOBENZYLGUANIDINE I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AGED; ARTICLE; BONE; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; LYMPH NODE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYMIC CARCINOID; THYMOMA; TUMOR DIAGNOSIS; TUMOR VOLUME;

3-IODOBENZYLGUANIDINE; AGED; BONE NEOPLASMS; CARCINOID TUMOR; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M MEDRONATE; THYMUS NEOPLASMS;

EID: 35748939974     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2007.01161.x     Document Type: Article

References (12)

1. Rosai J, Higa E. Mediastinal endocrine neoplasm, of probable thymic origin, related to carcinoid tumor: clinicopathologic study of 8 cases. Cancer 1972 29 : 1061 74.
2. Belhocine T, Foidart J, Rigo P, Najjar F, Thiry A et al. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlation with the pathological indexes p53 and Ki-67. Nucl. Med. Commun. 2002 23 : 727 34.
3. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J. Clin. Endocrinol. Metab. 2001 86 : 895 902.
4. 131I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl. Med. Commun. 2002 23 : 735 41.
5. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981 48 : 2485 92.
6. de Montpreville VT, Macchiarini P, Dulmet E. Thymic neuroendocrine carcinoma (carcinoid): a clinicopathologic study of fourteen cases. J. Thorac. Cardiovasc. Surg. 1996 111 : 134 41.
7. Le Rest C, Bomanji JB, Costa DC, Townsend CE, Visvikis D et al. Functional imaging of malignant paragangliomas and carcinoid tumours. Eur. J. Nucl. Med. 2001 28 : 478 82.
8. Jadvar H, Segall GM. False-negative fluorine-18-FDG PET in metastatic carcinoid. J. Nucl. Med. 1997 38 : 1382 3.
9. Groves AM, Mohan HK, Wegner EA, Hain SF, Bingham JB et al. Positron emission tomography with FDG to show thymic carcinoid. Am. J. Roentgenol. 2004 182 : 511 3.
10. 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J. Surg. 1998 22 : 588 92.
11. Reubi JC, Kvols LK, Waser B, Nagorney DM, Heitz PU, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 1990 50 : 5969 77.
12. Adams S, Baum RP, Hertel A, Schumm-Drager PM, Usadel KH et al. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen. Nucl. Med. Commun. 1998 19 : 641 7.